Zanubrutinib led to significant PFS improvements compared with bendamustine plus rituximab in patients with CLL or SLL. The overall efficacy of tisagenlecleucel was similar between the two groups. Flu/Cy led to more profound lymphocytopenia ... Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.